Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shilpa Eyes History At It Nudges Closer To Aflibercept Opportunity In India

Shilpa Biologicals Division Also Has Adalimumab In Its Sights

Executive Summary

Amid growing moves in India for local manufacturers to make and supply biosimilars, Shilpa’s biologics division has moved a step closer to becoming the first Indian company to initiate clinical trials for a biosimilar to Regeneron’s Eylea treatment for ophthalmic diseases.

You may also be interested in...

Pressure Mounts On Zydus Cadila In Q3 As Vaccine Launch Looms

Zydus Cadila found itself under pressure during Q3 following a lack of demand for COVID-19 therapeutics in India and reduced mesalamine sales in the US – but, heading into H2, exports of its novel COVID-19 vaccine ZyCov-D, as well as a number of biosimilar launches, could see its luck begin to turn.

Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk

Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.

Dr Reddy’s Pilots Sputnik V Soft Launch In India, Explores CAR-T Space

Dr Reddy’s initiates pilot roll-out of imported Russian vaccine Sputnik V, currently priced at about $13.50 per dose in India, and indicates that it hopes to bring the single-dose version Sputnik Light to the country. The Indian company also strikes a deal with a Chinese firm for a CAR-T cell therapy, an area where it hopes to “pick up skills”.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts